Phase 4 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any sex
- People who have been diagnosed with, or are strongly suspected of having, cancer of the stomach or oesophagus (gastroesophageal adenocarcinoma), based on CT, PET, or other scans (Cohort 1) — or people diagnosed with appendix cancer (appendiceal adenocarcinoma) where cancer spread to the lining of the abdomen is strongly suspected (Cohort 2)
- People for whom surgery is planned — either to remove a stomach or oesophageal tumour, or to perform a keyhole procedure to assess how far the cancer has spread inside the abdomen
- People who are willing to stop taking folate, folic acid, or any supplements containing folate at least 48 hours before receiving the study drug (CYTALUX)
- People who are willing to provide written consent to participate in the research
Who may not be able to join:
- People with any medical condition that the trial doctors believe could put them at risk during the study
- People who have previously had a severe allergic reaction (anaphylaxis) to products containing indocyanine green, a dye used in near-infrared imaging — people with a history of severe allergic reactions of unknown cause will need further assessment before joining
- People who have a known allergy to any ingredient in CYTALUX™ (pafolacianine) injection
- People facing psychological, family, social, or geographical circumstances that may make it difficult to follow the study requirements or attend follow-up appointments
- People with a known sensitivity to fluorescent light
- Women who are pregnant or planning to become pregnant during the study period
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Miguel Burch, MD, Cedars-Sinai Medical Center
Phone: 310-423-1542
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Feasibility of CYTALUX™ (pafolacianine) with near-infrared (NIR) fluorescent imaging
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.